Data Requirements for Patenting Biotech/Pharma Inventions in China and the EU

In Webinars

1 July, 2020

This interactive webinar considers the filing and post-filing data requirements for biotechnology and pharmaceutical-related inventions in China and the EU. Xiaofan Chen, Hai Liu and Helle Friis Svenstrup from AWA’s Asian and European offices explain the minimum data requirements during filing and also the criteria for supplementary data. They also consider the use of post-grant data as evidence during invalidation proceedings. Understanding the differences between the European and Chinese regimes is essential for applicants to be successful.

 

 

 

You may also be interested in:

MedTrace receives $30 million investment fuelling US expansion and new business area

AWA’s client MedTrace Pharma A/S has received nearly $30 million from Swiss-based Swisscanto Invest and Danish investors ATP and

Read more...

Lego’s compensation increased tenfold by appeal court

On 1 April 2020 the Guangdong Higher People’s Court announced that it had awarded Danish toymaker Lego Rmb30 million

Read more...

China’s president pledges stronger IP enforcement

China’s president Xi Jinping has reiterated the country’s commitment to strengthening intellectual property protection and enforcement through higher damages

Read more...

Mobile Sliding Menu